Industry Urges FDA To Move Faster In Using Models For Regulatory Decisions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA holds the key to making model-based drug development and drug-disease model libraries successful, speakers at a Jan. 24-25 Drug Industry Association meeting concluded
You may also be interested in...
Pharmacometric Reviews Increasingly Influence FDA Regulatory Decisions
Drug makers should routinely perform exposure-response analyses across Phase II and III studies to find consistencies across trials, FDA said in a recent survey of 31 NDAs submitted between 2005 and 2006.
FDA, Industry Unveil Mechanistic Trial Simulation Models
FDA partnered with industry to create four trial simulation models for Parkinson's disease, diabetes, depression and measuring cancer progression, which were unveiled at the Jan. 24-25 Drug Industry Association meeting on "Sharing Knowledge To Improve Clinical Drug Development and Regulatory Decisions.
FDA, Industry Unveil Mechanistic Trial Simulation Models
FDA partnered with industry to create four trial simulation models for Parkinson's disease, diabetes, depression and measuring cancer progression, which were unveiled at the Jan. 24-25 Drug Industry Association meeting on "Sharing Knowledge To Improve Clinical Drug Development and Regulatory Decisions.